Septerna (NASDAQ:SEPN) COO Sells $115,880.00 in Stock

Septerna, Inc. (NASDAQ:SEPN) COO Elizabeth Bhatt sold 4,000 shares of the stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $28.97, for a total value of $115,880.00. Following the completion of the sale, the chief operating officer owned 174,209 shares of the company’s stock, valued at $5,046,834.73. The trade was a 2.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Septerna Trading Up 0.7%

Shares of SEPN stock opened at $27.28 on Monday. Septerna, Inc. has a 1-year low of $4.66 and a 1-year high of $31.37. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of -18.07 and a beta of 3.86. The stock’s fifty day simple moving average is $26.73 and its 200-day simple moving average is $21.78.

Institutional Trading of Septerna

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Group One Trading LLC increased its holdings in shares of Septerna by 111.8% during the 4th quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after acquiring an additional 8,955 shares during the last quarter. Global Retirement Partners LLC acquired a new position in Septerna during the fourth quarter valued at approximately $35,000. Russell Investments Group Ltd. bought a new position in shares of Septerna in the third quarter valued at approximately $36,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Septerna in the fourth quarter worth $53,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Septerna during the 4th quarter worth $61,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a report on Thursday, January 22nd. Wells Fargo & Company upgraded shares of Septerna from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $18.00 to $28.00 in a research note on Friday, November 14th. Zacks Research lowered shares of Septerna from a “hold” rating to a “strong sell” rating in a research note on Friday, January 23rd. HC Wainwright upped their price target on shares of Septerna from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, January 20th. Finally, Raymond James Financial started coverage on Septerna in a research report on Friday, December 19th. They set a “strong-buy” rating and a $38.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, Septerna has an average rating of “Moderate Buy” and a consensus target price of $33.83.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.